- Home
- PETS vs ASRT Comparison
PETS vs ASRT Comparison
Compare PETS & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | ASRT |
|---|---|---|
| Founded | 1996 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 75.1M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | PETS | ASRT |
|---|---|---|
| Price | $3.42 | $9.60 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.20 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 1.2M | 63.0K |
| Earning Date | 02-09-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $198,265,000.00 | $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $1.57 | $7.71 |
| 52 Week High | $5.58 | $15.15 |
Technical Indicators
Market Signals| Indicator | PETS | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 60.35 | 85.48 |
| Support Level | $3.23 | $9.11 |
| Resistance Level | $3.70 | $9.50 |
| Average True Range (ATR) | 0.18 | 0.46 |
| MACD | -0.04 | 0.20 |
| Stochastic Oscillator | 50.87 | 93.17 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.